スダ サトシ   SUDA Satoshi
  須田 智
   所属   埼玉医科大学  医学部 国際医療センター 神経内科・脳卒中内科
   職種   教授
論文種別 学術雑誌(原著)
言語種別 英語
査読の有無 査読なし
表題 Prior direct oral anticoagulant dosage and outcomes in patients with acute ischemic stroke and non-valvular atrial fibrillation: A sub-analysis of PASTA registry study
掲載誌名 正式名:Journal of the Neurological Sciences
ISSNコード:0022-510X
掲載区分国外
出版社 Elsevier BV
巻・号・頁 434,120163-120163頁
著者・共著者 Takafumi Mashiko,Shigeru Fujimoto,Satoshi Suda,Arata Abe,Yasuyuki Iguchi,Yoshiki Yagita,Takao Kanzawa,Seiji Okubo,Kenichi Todo,Mineo Yamazaki,Nobuhito Nakajima,Kimito Kondo,Takeshi Inoue,Takeshi Iwanaga,Yuka Terasawa,Kensaku Shibazaki,Kazumi Kimura
発行年月 2022/03
概要 BACKGROUND AND PURPOSE: Prescribing under-dose direct oral anticoagulants (DOACs) for non-valvular atrial fibrillation (NVAF) is alerted to increase cardiovascular events or death. However, the association between dose selection of DOACs and the clinical course remains unclear. This study aimed to propose a novel criterion for selecting the DOAC dose and investigate clinical characteristics of ischemic stroke (IS) under this criterion. METHODS: We assessed the pooled prospective multicenter registry data of stroke patients taking anticoagulant agents, including IS patients with NVAF and prior DOAC usage. The recommended dose according to the reduction criteria of each DOAC and the selected dose were identified for each patient, and patients were categorized into four groups: no alternative low-dose, selecting low-dose appropriately with all DOACs applicable for reduction criteria; selected low-dose, selecting low-dose appropriately or inappropriately despite at least one DOAC inapplicable for reduction criteria; selected standard-dose, appropriate standard-dose use; and absolute over-dose, inappropriate standard-dose regardless of criteria. We investigated the effects of dose selection of DOACs on short-term poor functional outcomes. RESULTS: 322 patients were included in the analysis. The prevalence of no alternative low-dose, selected low-dose, selected standard-dose, and absolute over-dose was 74 (23%), 144 (45%), 89 (27%), and 15 (5%), respectively. Multivariable analysis found that the selected low-dose group showed significantly poorer functional outcomes than the selected standard-dose group only in patients without renal dysfunction (OR, 2.60; 95% CI, 1.17-6.00; P = 0.0186). CONCLUSIONS: Selecting a low dose DOAC might be associated with poor functional outcomes in patients without renal dysfunction.
DOI 10.1016/j.jns.2022.120163
PMID 35121210